Profound Medical Enrolls Last Patients in Phase 2 Trial of Minimally Invasive Ablation Method

Profound Medical Enrolls Last Patients in Phase 2 Trial of Minimally Invasive Ablation Method
The pivotal Phase 2 trial evaluating TULSA-PRO system, a minimally invasive procedure that ablates prostate cancer tissue, has enrolled 87 percent of all estimated participants, Profound Medical announced. The TACT study has already tested the system in 96 men with localized, organ-confined prostate cancer. Arun Menawat, CEO of the Toronto-based company, said in a press release that it expects to

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *